Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. - Wikidata - awgldk - TriplyDB

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

http://www.wikidata.org/entity/Q33977056

about

MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression EGF receptor ligands: recent advances MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2 A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.Androgen receptor regulates SRC expression through microRNA-203 KLF4 functions as an activator of the androgen receptor through reciprocal feedback.Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.Understanding the CREB1-miRNA feedback loop in human malignancies.Deciphering the function of non-coding RNAs in prostate cancer.hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma.Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells.Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.Prognostic significance of the expression of HER family members in primary osteosarcoma.MicroRNAs in prostate cancer: From function to biomarker discovery

P2860

Q26796592-7FB091EF-41F9-4414-A1D1-9917205C83B0 Q28066531-BE990435-D0D1-42FA-900E-0A00378548A8 Q33776774-A0E030A6-0858-40F9-AB8C-824A546ADB63 Q35568586-B0034862-DAEC-4891-AB1B-5E4377788C75 Q36962901-535754FB-7F75-4524-93CD-3FE8F4024872 Q37007828-3450F662-CF1D-4651-915A-DCA8BD08CD75 Q37269340-940AB088-AB1F-45C2-8610-7F83A48C49A6 Q37295473-7A03AFD4-F3AD-4712-B799-6A7A75D08D7D Q37525801-9525B688-3CEC-4909-BCDC-DF8CBC8F7F86 Q38771880-B9D5A107-5154-4510-8FB9-F50525ABE2B9 Q38802458-8F1F1ED7-C20F-4BF3-9EC0-5EEF183A8616 Q38843392-D03C197F-39F2-48BB-B97B-BEF63F05B4D3 Q39490672-74E0DA3F-BBA7-4A53-BDCC-285FA130F406 Q40507688-67E5FC6D-92AE-49AF-A86A-09015C2DED33 Q41098267-76E61276-12B8-4272-8D95-9ACBC266897A Q49887950-8EC00DA4-56BF-4238-BD86-E64341ECA3E7 Q50899921-05ACCA2D-3EE0-4E59-9ECD-997F36C85BE3 Q53367071-9F126C15-397B-479F-95F8-BF9085728D54 Q55108871-59AF0ABE-618D-4869-9FD3-8DF35ACEF577 Q55710586-0D48811A-CD6A-4A8A-9EE0-1A718B71DE7C Q57112127-2A88D65E-4777-4C64-9E0E-A1C2F548BE1A

P2860

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

http://www.wikidata.org/entity/Q33977056

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@ast

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@en

type

label

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@ast

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@en

prefLabel

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@ast

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@en

P1433

Q33977056-CCED9797-A4C6-488B-A43D-EC70C7992A2D

P1476

Q33977056-6EED66C0-A52D-4FDB-A0D7-9B7B1B5CE417

P2093

Q33977056-0365D8E3-3AA2-4DE3-A00C-0B9F546C6537

Q33977056-0CA2DB75-20B5-4EBD-9BB9-862658B691D4

Q33977056-0D6EA2BA-0936-481E-9810-C2B964EA884A

Q33977056-13CC15F4-4E77-4D86-931F-E59A88D90611

Q33977056-22A8AD91-1128-4450-A5C5-F2DFBED53609

Q33977056-29C04ADB-A36C-453A-B44D-5BCA72D927A4

Q33977056-2B512A9C-8B32-47FA-B5A0-5753FECFBFFE

Q33977056-2D8B5464-387D-4F78-9CF8-B5E71CE06548

Q33977056-35C1A1AB-71D9-472D-8706-43B68FDF8A75

Q33977056-81D2CA11-06DB-4812-9FB3-E1AA31F1F784

P2860

Q33977056-0D8868F6-7A35-44DF-A44C-A377CB1882AE

Q33977056-18DFA6FA-C01F-409D-A2EE-4CC3C7081757

Q33977056-1A995B36-04C4-45B2-B0C3-6714E36FA96F

Q33977056-1BF194E2-8BE6-4252-83DD-C7AF24BE921B

Q33977056-2599F6C8-8B29-4923-A035-86ECE039CDE0

Q33977056-279E2ED5-7B76-4C47-BEFA-210E7B7970B1

Q33977056-30E98B02-6635-48C8-9063-0FCBFF93FCE9

Q33977056-319E3233-D841-408D-A4FA-35017F76F2CC

Q33977056-3B96791E-72EA-4144-AF48-008CB908EA37

Q33977056-3FA14B16-5605-4005-9277-34B8430BB6A8

P304

Q33977056-E8BAACDA-4093-4D72-B564-FEDA1CC5E0CA

P31

Q33977056-C5E428D6-1FFF-4C2A-AAB8-AC0DC3A4B45B

P356

Q33977056-42B1295C-8937-444C-A5A3-E5581F5AAD63

P407

Q33977056-E9FA0C91-4505-4041-A9A0-B017CC750CE4

P433

Q33977056-8C8FFE01-8810-4B2A-ACF3-EAC62BFA0473

P478

Q33977056-2CA7E0ED-9221-4400-9549-87E30361338E

P577

Q33977056-6B6541AA-E80B-494D-B436-11891ED3238E

P5875

Q33977056-172E28BD-1A62-48DF-ABA7-1F426904830A

P698

Q33977056-C6EAA323-0000-4186-80AD-3EB80806556A

P932

Q33977056-15FBFC4B-1E3D-446F-87EB-41B6F90DA020

P356

ONCOTARGET.1994

P1433

P1476

Loss of EGFR signaling regulat ...... kinase inhibitors resistance.

@en

P2093

Ben Barrett

http://www.w3.org/2001/XMLSchema#string

Florent Suau

http://www.w3.org/2001/XMLSchema#string

Jiaoti Huang

http://www.w3.org/2001/XMLSchema#string

Juan Juan Yin

http://www.w3.org/2001/XMLSchema#string

Kathleen Kelly

http://www.w3.org/2001/XMLSchema#string

Lei Fang

http://www.w3.org/2001/XMLSchema#string

Man Kit Siu

http://www.w3.org/2001/XMLSchema#string

Orla Casey

http://www.w3.org/2001/XMLSchema#string

Paul Hynes

http://www.w3.org/2001/XMLSchema#string

Wassim Abou-Kheir

http://www.w3.org/2001/XMLSchema#string

P2860

Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo

The Hallmarks of Cancer

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

MicroRNAs: target recognition and regulatory functions

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

P304

3770-3784

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1994

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263739535

http://www.w3.org/2001/XMLSchema#string

P698

25004126

http://www.w3.org/2001/XMLSchema#string

P932

4116519

http://www.w3.org/2001/XMLSchema#string